<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706234</url>
  </required_header>
  <id_info>
    <org_study_id>S21(a)/2017</org_study_id>
    <nct_id>NCT04706234</nct_id>
  </id_info>
  <brief_title>Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies</brief_title>
  <acronym>FEEMSA</acronym>
  <official_title>Prospective Observational Study for the Systematic Assessment of Laryngopharyngeal Function in Patients With Multiple System Atrophy, Parkinson's Disease and 4repeat Tauopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kliniken Beelitz GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kliniken Beelitz GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional observational study designed to systematically record the&#xD;
      results of routine laryngeal examinations and specific characteristics of dysphagia in&#xD;
      patients with multiple system atrophy (MSA), Parkinson's disease (PD) and progressive&#xD;
      supranuclear palsy (PSP) and related 4repeat tauopathies. The results of a fiberoptic /&#xD;
      flexible endoscopic evaluation of swallowing (FEES) while performing a structured task&#xD;
      protocol will be recorded. If available, laryngeal electromyography (EMG) results will also&#xD;
      be recorded. In addition to the examination results, demographic and disease-specific data&#xD;
      are collected, and two questionnaires, the Swallowing Disturbance Questionnaire for&#xD;
      Parkinson's Disease (SDQ-PD) and the swallowing specific Quality Of Life Questionnaire&#xD;
      (SWALQOL), are administered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple system atrophy (MSA) is a sporadic progressive neurodegenerative disorder caused by&#xD;
      oligodendroglial aggregation of α-synuclein affecting predominantly the nigrostriatal,&#xD;
      olivo-ponto-cerebellar, and autonomic systems,resulting in a clinical presentation of&#xD;
      dysautonomia combined with either predominantly parkinsonian (MSA-P) or cerebellar (MSA-C)&#xD;
      symptoms of varying severity.In its early stage, the diagnosis of MSA according to the second&#xD;
      consensus criteria can be challenging. Therefore, the Movement Disorders Society MSA study&#xD;
      group recently addressed the importance of developing valuable diagnostic tools for securing&#xD;
      an early diagnosis in patients with MSA not only to estimate disease prognosis but also to&#xD;
      early initiate novel, potentially disease-modifying treatments in clinical trials. Despite&#xD;
      laryngopharyngeal dysfunction being associated with decreased life expectancy and quality of&#xD;
      life, systematic assessment of these functions in MSA is scarce. Previously, an&#xD;
      easy-to-implement MSA-FEES task-protocol was suggested to systematically assess&#xD;
      laryngopharyngeal function.&#xD;
&#xD;
      A pilot study on 8 patients with MSA not only showed that the task protocol was feasible and&#xD;
      well tolerated, but also that laryngopharyngeal symptoms where highly prevalent despite the&#xD;
      lack of clinical presentation (Warnecke et. al 2019). Moreover, irregular arytenoid&#xD;
      cartilages movements where present in all MSA-patients when performing this task protocol,&#xD;
      suggesting this symptom could serve as a clinical marker to identify MSA-patients.&#xD;
&#xD;
      Following this pilot study, an observational two center study assessed 57 MSA patients with&#xD;
      this protocol and compared findings to an age-matched cohort of PD-patients (Gandor et al.&#xD;
      2020). While only 43.9% of MSA patients had clinical symptoms of laryngeal dysfunction, 93%&#xD;
      showed laryngeal abnormalities during FEES performing the task-protocol. 91.2% of&#xD;
      MSA-patients showed irregular arytenoid cartilages movements. In contrast, only one PD&#xD;
      patient showed laryngeal abnormalities with vocal fold motion impairment, but not irregular&#xD;
      arytenoid cartilages movements. This study suggests that irregular arytenoid cartilages&#xD;
      movements allow differentiating MSA from PD with a sensitivity of 0.9 and a specificity of&#xD;
      1.0.&#xD;
&#xD;
      The aim of this FEEMSA trial is to continue recruitment of patients with MSA and PD and&#xD;
      systematically assess laryngopharyngeal function in an even larger cohort. Moreover, patients&#xD;
      with PSP and related 4repeat tauopathies will also be recruited at eligible sites to compare&#xD;
      results from this cohort to results in MSA and PD. If available, laryngeal EMG will also be&#xD;
      recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>laryngeal movement disorders</measure>
    <time_frame>1 day</time_frame>
    <description>occurrence of vocal fold motion impairment, paradoxical vocal fold motion, vocal fold fixation or involuntary irregular arytenoid cartilages movements when assessed with the task-protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dysphagia</measure>
    <time_frame>1 day</time_frame>
    <description>occurrence of dysphagic symptoms when assessed with the task-protocol</description>
  </primary_outcome>
  <other_outcome>
    <measure>laryngeal EMG findings</measure>
    <time_frame>1 day</time_frame>
    <description>abnormalities recorded on laryngeal EMG showing denervation, dystonic co-activation or myoclonic discharges</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple System Atrophy</condition>
  <condition>Parkinson Disease</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Multiple System Atrophy</arm_group_label>
    <description>Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progressive supranuclear palsy</arm_group_label>
    <description>Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson Disease</arm_group_label>
    <description>Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited at the participating sites from outpatient's clinics or admitted&#xD;
        patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of probable or possible multiple system atrophy according to current&#xD;
             consensus criteria (Gilman et al. 2008) or&#xD;
&#xD;
          -  diagnosis of probable or possible PSP according to the the Movement Disorders Society&#xD;
             (MDS) diagnostic criteria (Höglinger et al. 2017) or&#xD;
&#xD;
          -  diagnosis of Parkinson's disease according to the MDS diagnostic criteria (Postuma et&#xD;
             al 2015)&#xD;
&#xD;
          -  Hoehn and Yahr Stage within the range of I-V&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not sign the consent form&#xD;
&#xD;
          -  Patients who have contraindications for performing fiber endoscopic laryngoscopy and&#xD;
             swallowing examination.&#xD;
&#xD;
          -  Pregnancy in female patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florin Gandor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Movement Disorders Hospital Beelitz-Heilstätten, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florin Gandor, MD</last_name>
    <phone>+493320422781</phone>
    <phone_ext>22781</phone_ext>
    <email>gandor@kliniken-beelitz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Warnecke, MD</last_name>
    <phone>+49251980</phone>
    <phone_ext>2902</phone_ext>
    <email>tobias.warnecke@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology and Department of ENT, Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Wenning, MD, PhD, MSc</last_name>
      <phone>+43676596</phone>
      <phone_ext>4772</phone_ext>
      <email>gregor.wenning@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Alessandra Fanciulli, MD, PhD</last_name>
      <phone>+435125048</phone>
      <phone_ext>3238</phone_ext>
      <email>Alessandra.Fanciulli@i-med.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Klaus Seppi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claus Pototschnig, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Krismer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Galvan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian Leys, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Raccagni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Sideroff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Granata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kassubek, MD</last_name>
      <email>jan.kassubek@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Kassubek, MD</last_name>
      <email>rebecca.kassubek@uni-ulm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Beate Lindner-Pfleghar, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Hospital - Kliniken Beelitz</name>
      <address>
        <city>Beelitz-Heilstätten</city>
        <state>Brandenburg</state>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florin Gandor, MD</last_name>
      <phone>+49332042</phone>
      <phone_ext>2781</phone_ext>
      <email>gandor@kliniken-beelitz.de</email>
    </contact>
    <contact_backup>
      <last_name>Doreen Gruber, MD</last_name>
      <phone>+49332042</phone>
      <phone_ext>2781</phone_ext>
      <email>gruber@kliniken-beelitz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Annemarie Vogel, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Ebersbach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Günter Höglinger, MD</last_name>
      <email>hoeglinger.guenter@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Pannewitz-Makaj, MD</last_name>
      <email>Pannewitz-Makaj.Katharina@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Schrader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Warnecke, MD</last_name>
      <phone>+49251834</phone>
      <phone_ext>8216</phone_ext>
      <email>tobias.warnecke@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Inga Claus, MD</last_name>
      <email>inga.claus@ukmuenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sigrid Ahring</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Falkenburger, MD</last_name>
      <phone>+49351458</phone>
      <phone_ext>2532</phone_ext>
      <email>Bjoern.Falkenburger@dzne.de</email>
    </contact>
    <contact_backup>
      <last_name>Inaki Schniewind, MD</last_name>
      <email>Inaki.Schniewind@uniklinikum-dresden.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Movement Disorders Unit, Medical Center Tel Aviv</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Gurevich, MD</last_name>
      <email>tanyag@tlvmc.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Adi Ezra</last_name>
      <email>adil@tlvmc.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto delle Scienze Neurologiche, Azienda USL di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Giannini, MD, PhD</last_name>
      <email>giulia.giannini15@unibo.it</email>
    </contact>
    <contact_backup>
      <last_name>Luca Baldelli, MD</last_name>
      <email>luca.baldelli4@unibo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical University Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Friedman, MD, PhD</last_name>
      <email>andrzej.friedman@wum.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Madetko, MD</last_name>
      <email>natalia.madetko@wum.edu.pl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Unidad de Parkinson y Trastornos del Movimiento Instituto Clínic de Neurociencias, Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria J Marti, MD PhD</last_name>
      <phone>+34 93 227 57 85</phone>
      <email>mjmarti@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Perez, MD</last_name>
      <phone>+34 93 227 57 85</phone>
      <email>aperez3@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Isabel Vilaseca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Warnecke T, Vogel A, Ahring S, Gruber D, Heinze HJ, Dziewas R, Ebersbach G, Gandor F. The Shaking Palsy of the Larynx-Potential Biomarker for Multiple System Atrophy: A Pilot Study and Literature Review. Front Neurol. 2019 Mar 26;10:241. doi: 10.3389/fneur.2019.00241. eCollection 2019.</citation>
    <PMID>30972002</PMID>
  </reference>
  <reference>
    <citation>Gandor F, Vogel A, Claus I, Ahring S, Gruber D, Heinze HJ, Dziewas R, Ebersbach G, Warnecke T. Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker? Mov Disord. 2020 Dec;35(12):2174-2183. doi: 10.1002/mds.28220. Epub 2020 Aug 5.</citation>
    <PMID>32757231</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kliniken Beelitz GmbH</investigator_affiliation>
    <investigator_full_name>Dr. Florin Gandor, MD</investigator_full_name>
    <investigator_title>Consultant Neurologist</investigator_title>
  </responsible_party>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>clinical biomarker</keyword>
  <keyword>FEES</keyword>
  <keyword>laryngeal EMG</keyword>
  <keyword>irregular arytenoid cartilages movements</keyword>
  <keyword>dysphagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

